These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19850779)

  • 1. Interaction between liquid protein solution and omeprazole suspension.
    Freeman KL; Trezevant MS
    Am J Health Syst Pharm; 2009 Nov; 66(21):1901-2. PubMed ID: 19850779
    [No Abstract]   [Full Text] [Related]  

  • 2. Stability of partial doses of omeprazole-sodium bicarbonate oral suspension.
    Johnson CE; Cober MP; Ludwig JL
    Ann Pharmacother; 2007 Dec; 41(12):1954-61. PubMed ID: 17956960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability and viscosity of a flavored omeprazole oral suspension for pediatric use.
    Burnett JE; Balkin ER
    Am J Health Syst Pharm; 2006 Nov; 63(22):2240-7. PubMed ID: 17090745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of omeprazole in an extemporaneously prepared oral liquid.
    Quercia RA; Fan C; Liu X; Chow MS
    Am J Health Syst Pharm; 1997 Aug; 54(16):1833-6. PubMed ID: 9269520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
    Kambia NK; Luyckx M; Dine T; Dupin-Spriet T; Gressier B; Brunet C
    J Clin Pharm Ther; 2009 Feb; 34(1):25-31. PubMed ID: 19125900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate-release oral proton pump inhibitors: Panacea or a flash in the pan?
    Chan FK
    J Gastroenterol Hepatol; 2010 Jan; 25(1):6-7. PubMed ID: 20136970
    [No Abstract]   [Full Text] [Related]  

  • 7. Dissolution test for liquid formulations of omeprazole enteric-coated products.
    Jang HJ; Kang BC; Shin WG; Lee S
    Ann Pharmacother; 2003 Jan; 37(1):150-1. PubMed ID: 12503954
    [No Abstract]   [Full Text] [Related]  

  • 8. Omeprazole--a new formulation.
    Armstrong D
    Can J Gastroenterol; 1997; 11(8):655-6. PubMed ID: 9459043
    [No Abstract]   [Full Text] [Related]  

  • 9. Instantaneous enteric nano-encapsulation of omeprazole: pharmaceutical and pharmacological evaluation.
    Bendas ER; Abdelbary AA
    Int J Pharm; 2014 Jul; 468(1-2):97-104. PubMed ID: 24746414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omeprazole/Antacid-powder suspension-Santarus: omeprazole/sodium bicarbonate powder-Santarus, SAN 05.
    Drugs R D; 2004; 5(6):349-50. PubMed ID: 15563239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems.
    Boussery K; De Smet J; De Cock P; Vande Velde S; Mehuys E; De Paepe P; Remon JP; Van Bocxlaer JF; Van Winckel M
    Br J Clin Pharmacol; 2011 Dec; 72(6):990-6. PubMed ID: 21658093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid state interactions between the proton pump inhibitor omeprazole and various enteric coating polymers.
    Stroyer A; McGinity JW; Leopold CS
    J Pharm Sci; 2006 Jun; 95(6):1342-53. PubMed ID: 16625655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid.
    Chuong MC; Taglieri CA; Kerr SG
    Int J Pharm Compd; 2017; 21(6):500-512. PubMed ID: 29220339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photocatalytic and photoelectrocatalytic degradation of the drug omeprazole on nanocrystalline titania films in alkaline media: Effect of applied electrical bias on degradation and transformation products.
    Tantis I; Bousiakou L; Frontistis Z; Mantzavinos D; Konstantinou I; Antonopoulou M; Karikas GA; Lianos P
    J Hazard Mater; 2015 Aug; 294():57-63. PubMed ID: 25855613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid chromatographic resolution of proton pump inhibitors including omeprazole on a ligand exchange chiral stationary phase.
    Ha JJ; Choi HJ; Jin JS; Jeong ED; Hyun MH
    J Chromatogr A; 2010 Oct; 1217(41):6436-41. PubMed ID: 20828702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidation of R- and S-omeprazole stereoselectively mediated by liver microsomal cytochrome P450 2C19 enzymes from cynomolgus monkeys and common marmosets.
    Uehara S; Kawano M; Murayama N; Uno Y; Utoh M; Inoue T; Sasaki E; Yamazaki H
    Biochem Pharmacol; 2016 Nov; 120():56-62. PubMed ID: 27641812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid.
    Chuong M; Taglieri CA; Huang SY; Sariol A; Kitigawa R; Barman K; Mistry A; Harris DL; Kerr SG
    Int J Pharm Compd; 2019; 23(6):504-510. PubMed ID: 31751947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revealing the Mechanistic Pathway of Acid Activation of Proton Pump Inhibitors To Inhibit the Gastric Proton Pump: A DFT Study.
    Jana K; Bandyopadhyay T; Ganguly B
    J Phys Chem B; 2016 Dec; 120(51):13031-13038. PubMed ID: 27992223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omeprazole/antacid-powder suspension--Santarus: Acitrel, Rapinex Powder for oral suspension, SAN 05.
    Drugs R D; 2004; 5(4):234-5. PubMed ID: 15230632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Stability Study of an Omeprazole Suppository for Infants.
    Bestebreurtje P; Roeleveld N; Knibbe CAJ; van Sorge AA; Plötz FB; de Wildt SN
    Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):627-633. PubMed ID: 32594306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.